Miiskin appoints new CEO and raises $2.25 million

Copenhagen, September 2, 2026

Following more than 20,000 dermatology consultations in the US, Miiskin has appointed Tina Ravn as CEO and raised $2.25 million in new funding. The innovative health-tech company is strengthening its commercial and organizational capabilities to accelerate growth in the rapidly expanding US teledermatology market.

Access to dermatologists remains a significant challenge in the US. The average wait time for a dermatology appointment has increased by 50 percent since 2004 and now stands at 36.5 days.

Miiskin offers a digital alternative, connecting patients with independent, board-certified dermatologists online. On average, patients receive a response from a dermatologist within 14.2 hours.

This positions Miiskin in a US teledermatology market projected to grow from $4.3 billion in 2024 to $11.3 billion by 2030.

Tina Ravn formally took over as CEO of Miiskin in August. Her appointment marks a new phase for the company, with an increased commercial focus and plans to accelerate growth in the US. Founder Jon Friis will remain with Miiskin as Chief Information Officer.

Michael Shalmi, Chairman of the Board at Miiskin, says:

“Digital dermatology is a rapidly growing market driven by a clear need for faster and easier access to specialist care. Miiskin has reached a stage where the priority is to scale and strengthen its position as the market develops. Tina brings significant commercial and communications experience, as well as a strong track record in the digitalization of healthcare. She is the right person to lead Miiskin through its next phase of growth.”

Strong patient retention provides a foundation for growth

Of the more than 20,000 consultations completed through Miiskin, approximately 40 percent are from returning patients. For Miiskin, this is an important indication that patients see value in the platform and in the continuity of care it provides throughout their treatment.

The company’s next priority is to significantly expand the number of patients discovering and using the platform.

Tina Ravn, CEO of Miiskin, says:

“We have demonstrated that patients use Miiskin and, importantly, that many choose to return. That is a strong signal of the potential we see in the platform. Our next commercial priority is to make Miiskin accessible to many more people. But growth is not simply about marketing. Patients need to feel confident and supported throughout the entire experience — from discovering Miiskin and starting a consultation to communicating with their dermatologist and receiving follow-up care.”

Doctors, not AI, make the diagnosis

Artificial intelligence is reshaping teledermatology, with a growing number of digital services offering skin assessments performed partly or entirely by AI. But research indicates that patients continue to place significant value on human medical expertise.

According to published research, 84 percent of patients prefer a diagnosis made by a physician rather than AI, while 74 percent say it is important that their dermatologist is board-certified.

At Miiskin, clinical assessments, diagnoses, and treatments are provided exclusively by independent, US board-certified dermatologists. Patients submit images and relevant medical information digitally, allowing the dermatologist to assess the case asynchronously. When follow-up care is needed, patients can continue with the same dermatologist.

Tina Ravn says:

“Technology and AI should support dermatologists and make high-quality dermatology care easier to access — not replace the dermatologist. We see strong demand for a model that combines digital convenience with the confidence and continuity of being treated by a qualified specialist.”

New leadership and $2.25 million in funding

Tina Ravn brings more than 20 years of experience across the international pharmaceutical and healthcare industries. Her background includes senior roles at Pfizer, where she led the digitalization of engagement with patients and healthcare professionals across 25 markets.

Alongside the leadership transition, Miiskin has raised $2.25 million from new and existing investors to support the company’s next phase of growth.

As CEO, Ravn will work closely with Miiskin’s board. Chairman Michael Shalmi previously held senior roles at Novo Holdings, where he was responsible for major investments, while board member Peter G. Jørgensen is co-founder and Group CCO of Boozt.

Founder Jon Friis will continue at Miiskin as Chief Information Officer.

Jon Friis says:

“Miiskin has reached a stage where strengthening our commercial leadership is essential to realizing the opportunity ahead of us. I look forward to working closely with Tina and seeing her lead Miiskin into its next phase, with the ambition of making high-quality dermatology care accessible to many more patients across the US.”

About Miiskin

Miiskin is a Danish health-tech company focused on making dermatology care more accessible in the United States.

• Founded in Denmark in 2015 and re-established in 2022.
• Provides digital access to dermatological care across the US.
• Clinical assessments, diagnoses, and treatments are provided exclusively by independent, US board-certified dermatologists.
• More than 20,000 dermatology consultations have been completed through the platform.
• The average time from submitting a consultation to receiving a dermatologist’s response is 14.2 hours.
• Approximately 40 percent of consultations are from returning patients.
• Miiskin raised $2.25 million from new and existing investors in July 2026.

Media Contacts

Martin Møller
CMO at Miiskin
[email protected]